INDIA – Lupin has completed the acquisition of a portfolio of brands from Anglo-French Drugs & Industries (AFDIL) and its Associates.
Lupin’s India Formulation business will be strengthened by the addition of a rapidly expanding portfolio of vitamins, minerals, supplements, and neurological products.
The acquisition of the AFDIL brands moves Lupin one step closer to establishing itself as India’s leading pharmaceutical company.
Anglo-French Drugs and Industries began as a medicine importer in 1923 and has since developed over 300 products that are sold all over the world.
The company’s brands are market leaders in the nutraceuticals, central nervous system (CNS), skin, and respiratory segments.
Lupin is a multinational pharmaceutical corporation. The company develops and commercializes a diverse range of branded and generic formulations, biotechnology products, and APIs in over 100 markets worldwide, including the United States, India, South Africa, and Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East.
Nilesh Gupta, Managing Director, Lupin said, “India is critical in shaping Lupin’s growth story, going forward. This acquisition strengthens our position in the Indian market, where we have already established ourselves as a leading provider of quality pharmaceuticals and a trusted partner.
“With this enhanced portfolio, Lupin will have a stronger market presence, providing healthcare professionals and patients with a more meaningful and comprehensive product offering.“
Shailesh Gadre, Founder, GCV Life, was the exclusive adviser for the transaction, the statement concluded.
In the meantime, Lupin has also announced the launch of Merzee capsules, a medication used to prevent pregnancy, in the US market.
Lupin Ltd said in a statement that the product has been launched in the US market under an exclusive license, marketing, and distribution agreement with Slayback Pharma LLC.
Slayback had previously announced that this product would be available in the United States in February 2021.
Merzee (norethindrone acetate, ethinyl estradiol, and ferrous fumarate capsules), 1 mg/20 mcg is the generic equivalent of Allergan Pharmaceuticals’ Taytulla capsules.
According to IQVIA MAT February 2022 data, Norethindrone acetate and ethinyl estradiol capsules, as well as ferrous fumarate capsules, 1 mg/20 mcg, had an estimated annual sale of US$90 million in the United States.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
